Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Y0001516

Rivastigmine hydrogen tartrate

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Rivastigmine tartrate, ENA-713, Ethylmethyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester, N-Ethyl-N-methyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester tartrate, S-Rivastigmine tartrate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C14H22N2O2 · C4H6O6
Número de CAS:
Peso molecular:
400.42
Código UNSPSC:
41116107
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

rivastigmine

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

N([C@@H](C)c1cc(ccc1)OC(=O)N(CC)C)(C)C.O[C@@H]([C@H](O)C(=O)O)C(=O)O

InChI

1S/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-;1-,2-/m00/s1

Clave InChI

GWHQHAUAXRMMOT-RWALOXMOSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Rivastigmine hydrogen tartrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Acciones bioquímicas o fisiológicas

Rivastigmine is an orally available, brain penetrant, reversible cholinesterase inhibitor that enhances cognitive function in patients with Alzheimer′s and Parkinson′s diseases. Rivastigmine inhibits both butyrylcholinesterase and acetylcholinesterase.
Rivastigmine is an orally available, brain penetrant, reversible cholinesterase inhibitor.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Pictogramas

Skull and crossbonesEnvironment

Palabra de señalización

Danger

Frases de peligro

Clasificaciones de peligro

Acute Tox. 2 Oral - Aquatic Chronic 2

Código de clase de almacenamiento

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Galeno Rojas et al.
Medicina, 73(3), 213-223 (2013-06-05)
Cognitive impairment and dementia treatment costs are significant for health systems. According to national and international guidelines, recommended drugs for treatment of dementias are cholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine. Despite these guidelines recommendations, other nootropics, vasodilators and antioxidants
Katherine L Possin et al.
Movement disorders : official journal of the Movement Disorder Society, 28(10), 1384-1390 (2013-07-13)
The objective of this study was to investigate how acetylcholinesterase inhibitor (ChEI) treatment affects brain function in Parkinson's disease (PD). Twelve patients with PD and either dementia or mild cognitive impairment underwent task-free functional magnetic resonance imaging before and after
Agadi Hiremath Thippeswamy et al.
Journal of acupuncture and meridian studies, 6(4), 208-213 (2013-08-27)
The objective of this study was to evaluate the synergistic activity of Bacopa monniera with Rivastigmine against aluminum-chloride (AlCl3)-induced cognitive impairment in rats. Adult male Wistar rats were divided into ten groups (n = 10) and subjected to their assigned
Nastaran Majdi Nasab et al.
JPMA. The Journal of the Pakistan Medical Association, 62(7), 677-680 (2013-07-23)
To assess the efficacy of the Ginkgo biloba in patients with dementia of the Alzheimer type in slowing down the disease's degenerative progression and the patients' cognitive impairment compared with rivastigmine. Total 56 patients aged 50-75 years, suffering from dementia
Kevin R Peters
Journal of the American Geriatrics Society, 61(7), 1170-1174 (2013-05-29)
To highlight the utility of using an effect size analysis to communicate the effectiveness of treatment interventions. Secondary analysis. Previously published systematic review on cholinesterase inhibitors (ChEIs) in Alzheimer's disease. Individuals with mild to moderate Alzheimer's disease. Six-month randomized controlled

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico